Concomitant new diagnosis of systemic lupus erythematosus and COVID-19 with possible antiphospholipid syndrome. Just a coincidence? A case report and review of intertwining pathophysiology
Tóm tắt
In the midst of the COVID-19 pandemic, further understanding of its complications points towards dysregulated immune response as a major component. Systemic lupus erythematosus (SLE) is also a disease of immune dysregulation leading to multisystem compromise. We present a case of new-onset SLE concomitantly with COVID-19 and development of antiphospholipid antibodies. An 18-year-old female that presented with hemodynamic collapse and respiratory failure, progressed to cardiac arrest, and had a pericardial tamponade drained. She then progressed to severe acute respiratory distress syndrome, severe ventricular dysfunction, and worsening renal function with proteinuria and hematuria. Further studies showed bilateral pleural effusions, positive antinuclear and antidouble-stranded DNA antibodies, lupus anticoagulant, and anticardiolipin B. C3 and C4 levels were low. SARS-Cov-2 PCR was positive after 2 negative tests. She also developed multiple deep venous thrombosis, in the setting of positive antiphospholipid antibodies and lupus anticoagulant. In terms of pathophysiology, COVID-19 is believed to cause a dysregulated cytokine response which could potentially be exacerbated by the shift in Th1 to Th2 response seen in SLE. Also, it is well documented that viral infections are an environmental factor that contributes to the development of autoimmunity; however, COVID-19 is a new entity, and it is not known if it could trigger autoimmune conditions. Additionally, it is possible that SARS-CoV-2, as it happens with other viruses, might lead to the formation of antiphospholipid antibodies, potentially contributing to the increased rates of thrombosis seen in COVID-19.
Tài liệu tham khảo
Tsokos GC (2011) Systemic lupus erythematosus. N Engl J Med 365(22):2110–2121. https://doi.org/10.1056/nejmra1100359
Wang D et al (2020) Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. Jama 323(11):1061. https://doi.org/10.1001/jama.2020.1585
Qin C et al (2020) Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis. https://doi.org/10.1093/cid/ciaa248
Doaty S et al. (2016) “Infection and lupus: which causes which?” Curr Rheumatol Rep, vol. 18, no. 3, doi:https://doi.org/10.1007/s11926-016-0561-4.
Perl A (1999) Mechanisms of viral pathogenesis in rheumatic disease. Ann Rheum Dis 58(8):454–461. https://doi.org/10.1136/ard.58.8.454
Uthman IW, Gharavi AE (2002) Viral infections and antiphospholipid antibodies. Semin Arthritis Rheum 31(4):256–263. https://doi.org/10.1053/sarh.2002.28303
Caso F et al (2020) Could SARS-Coronavirus-2 trigger autoimmune and/or autoinflammatory mechanisms in genetically predisposed subjects? Autoimmun Rev 19(5):102524. https://doi.org/10.1016/j.autrev.2020.102524
Esposito S et al (2014) Infections and systemic lupus erythematosus. Eur J Clin Microbiol Infect Dis 33(9):1467–1475. https://doi.org/10.1007/s10096-014-2098-7
Zhang Y et al. (2020) “Coagulopathy and antiphospholipid antibodies in patients with Covid-19.” N Engl J Med, vol. 382, no. 17, doi:https://doi.org/10.1056/nejmc2007575.
Tincani A et al (2006) Heart involvement in systemic lupus erythematosus, anti-phospholipid syndrome and neonatal lupus. Rheumatology 45(suppl_4):iv8–iv13. https://doi.org/10.1093/rheumatology/kel308
Inciardi RM et al (2020) Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19). JAMA Cardiol. https://doi.org/10.1001/jamacardio.2020.1096
Castier MB et al (2000) Cardiac tamponade in systemic lupus erythematosus. Report of Four Cases. Arq Bras Cardiol 75(5):446–448. https://doi.org/10.1590/s0066-782x2000001100008
Kahl LE (1992) The spectrum of pericardial tamponade in systemic lupus erythematosus: report of ten patients. Arthritis Rheum 35(11):1343–1349. https://doi.org/10.1002/art.1780351115
Dabbagh MF et al (2020) Cardiac tamponade secondary to COVID-19. JACC: Case Rep. https://doi.org/10.1016/j.jaccas.2020.04.009
Hua A et al (2020) Life-threatening cardiac tamponade complicating myo-pericarditis in COVID-19. Eur Heart J. https://doi.org/10.1093/eurheartj/ehaa253
Kang Y et al (2020) Cardiovascular manifestations and treatment considerations in Covid-19. Heart. https://doi.org/10.1136/heartjnl-2020-317056
Alamoudi OSB, Attar SM (2015) Pulmonary manifestations in systemic lupus erythematosus: association with disease activity. Respirology 20(3):474–480. https://doi.org/10.1111/resp.12473
Wu J et al (2020) Interpretation of CT signs of 2019 novel coronavirus (COVID-19) pneumonia. Eur Radiol. https://doi.org/10.1007/s00330-020-06915-5
Rodriguez-Morales AJ et al (2020) Clinical, laboratory and imaging features of COVID-19: a systematic review and meta-analysis. Travel Med Infect Dis 34:101623. https://doi.org/10.1016/j.tmaid.2020.101623
Grasselli G et al (2020) Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. Jama. https://doi.org/10.1001/jama.2020.5394
Wang W et al (2020) Detection of SARS-CoV-2 in different types of clinical specimens. Jama. https://doi.org/10.1001/jama.2020.3786
Xie X et al. (2020) “Chest CT for typical 2019-NCoV pneumonia: relationship to negative RT-PCR testing.” Radiology, p. 200343., doi:https://doi.org/10.1148/radiol.2020200343
Guo Y-R et al. (2020) “The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status.” Mil Med Res, vol. 7, no. 1, doi:https://doi.org/10.1186/s40779-020-00240-0.
Cytokines and immunity to viral infections. Ramshaw IA, Ramsay AJ, Karupiah G, Rolph MS, Mahalingam S, Ruby JC Immunol Rev. 1997; 159():119–35.
Garcia D, Erkan D (2018) Diagnosis and management of the antiphospholipid syndrome. N Engl J Med 378(21):2010–2021. https://doi.org/10.1056/nejmra1705454
Panigada M et al (2020) Hypercoagulability of COVID-19 patients in intensive care unit. A report of thromboelastography findings and other parameters of hemostasis. J Thromb Haemost. https://doi.org/10.1111/jth.14850
Klok FA et al (2020) Incidence of thrombotic complications in critically Ill ICU patients with COVID-19. Thromb Res. https://doi.org/10.1016/j.thromres.2020.04.013
Schreiber K et al. “Antiphospholipid syndrome.” Nat Rev Dis Primers, vol. 4, no. 1, 2018, doi:https://doi.org/10.1038/nrdp.2017.103.
Asherson RA (2003) Antiphospholipid antibodies and infections. Ann Rheum Dis 62(5):388–393. https://doi.org/10.1136/ard.62.5.388
Martirosyan A et al. (2019) “Environmental triggers of autoreactive responses: induction of antiphospholipid antibody formation.” Front Immunol, vol. 10, doi:https://doi.org/10.3389/fimmu.2019.01609.
Channappanavar R et al. (1970) “Why tocilizumab could be an effective treatment for severe COVID-19?” J Transl Med, BioMed Central, translational-medicine.biomedcentral.com/articles/10.1186/s12967-020-02339-3.
Mehta P et al (2020) COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 395(10229):1033–1034. https://doi.org/10.1016/s0140-6736(20)30628-0
Zhao M (2020) “Cytokine storm and immunomodulatory therapy in COVID-19: role of chloroquine and anti-IL-6 monoclonal antibodies.” Int J Antimicrob Agents, p. 105982., doi:https://doi.org/10.1016/j.ijantimicag.2020.105982.